News Sentiment

KYNB sentiment intelligence

Kyntra Bio, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 56 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 7.23 Week of 17 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

75/100 classification confidence.

Company focus 47

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-4.9% over one week, +7.9% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Kyntra Bio Inc. (KYNB) Sheds 1.5% as Shares Test Key Support Zone - Counter Trend Trade

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 75/100 classification
One-week reaction -4.9% Price reacting lower
Trend fit Trend inactive 7.9% over four weeks
Fair value -54.6% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 39
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 47
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
TradingView 14
Market source 9
Stock Titan 8
Investing.com 5
dars.gov.et 3
Moomoo 3
GlobeNewswire 3
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 23
Earnings 22
Analyst action 5
Balance sheet 2
Guidance 2
Regulatory and legal 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-56 of 56
TradingView Direct company coverage

Kyntra Bio Presents New Roxadustat Data On Improvements In Patients With Anemia Due To Lower-Risk Myelodysplastic Syndromes

Kyntra Bio has unveiled new data regarding Roxadustat, showing its effectiveness in improving the condition of patients suffering from anemia due to lower-risk Myelodysplastic Syndromes. This information is released through Reuters and pertains to the company KYNB.

Tone
Positive 70/100
Event
Market update
Published
11 Jun 2026 20:09
Source
TradingView
Stock Titan Direct company coverage

Anemia MDS patients more often reached transfusion independence on roxadustat

Kyntra Bio announced new post hoc Phase 3 MATTERHORN data for roxadustat, showing improved transfusion independence in patients with lower-risk myelodysplastic syndromes (LR-MDS) regardless of ring sideroblast status. Roxadustat achieved transfusion independence in 48% of patient

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 20:09
Source
Stock Titan
Moomoo Direct company coverage

Kyntra Bio Receives Final $4 Million Payment Under 2025 Share Purchase Deal With AstraZeneca

Kyntra Bio announced it has received the final $4 million payment from AstraZeneca under a 2025 share purchase agreement. This payment concludes the deal, bringing the total funds received to $6 million. The agreement involved Kyntra Bio selling shares to AstraZeneca between 2023

Tone
Neutral 50/100
Event
Deals and strategy
Published
11 Jun 2026 07:39
Source
Moomoo
Associated Press Direct company coverage

Kyntra Bio: Q1 Earnings Snapshot

Tone
Neutral 50/100
Event
Earnings
Published
11 May 2026 20:28
Source
Associated Press